Biomarker‐based risk prediction in the community
暂无分享,去创建一个
A. Jaffe | R. Rodeheffer | M. Redfield | J. Burnett | C. Scott | Omar F. AbouEzzeddine | P. McKie | Horng H. Chen | G. Michael Felker
[1] Jackson T. Wright,et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.
[2] H. Soran,et al. Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment. , 2015, European heart journal.
[3] W. Qureshi,et al. Risk Stratification for Primary Prevention of Coronary Artery Disease: Roles of C-Reactive Protein and Coronary Artery Calcium , 2015, Current Cardiology Reports.
[4] L. Tilson,et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study , 2015, European journal of heart failure.
[5] M. Pencina,et al. Charting a roadmap for heart failure biomarker studies. , 2014, JACC. Heart failure.
[6] A. Jaffe,et al. High-sensitivity troponin I and amino-terminal pro--B-type natriuretic peptide predict heart failure and mortality in the general population. , 2014, Clinical chemistry.
[7] V. Salomaa,et al. ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality , 2014, Heart.
[8] R. McKelvie,et al. Prediction of clinical outcomes using B-type natriuretic peptides in the general population: a systematic review , 2014, Heart Failure Reviews.
[9] Jennifer G. Robinson,et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.
[10] E. Barrett-Connor,et al. Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study. , 2014, American heart journal.
[11] R. D. de Boer,et al. Clinical Risk Stratification Optimizes Value of Biomarkers to Predict New-Onset Heart Failure in a Community-Based Cohort , 2014, Circulation. Heart failure.
[12] J. Gaziano,et al. Plasma galectin 3 and heart failure risk in the Physicians' Health Study , 2014, European journal of heart failure.
[13] V. Salomaa,et al. High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. , 2014, European heart journal.
[14] R. Prager,et al. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. , 2013, Journal of the American College of Cardiology.
[15] C. Watson,et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. , 2013, JAMA.
[16] L. Lind,et al. Cardiac troponin I levels measured with a high-sensitive assay increase over time and are strong predictors of mortality in an elderly population. , 2013, Journal of the American College of Cardiology.
[17] D. Levy,et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. , 2012, Journal of the American College of Cardiology.
[18] D. Levy,et al. Prognostic Utility of Novel Biomarkers of Cardiovascular Stress: The Framingham Heart Study , 2012, Circulation.
[19] Hanyu Ni,et al. Prediction of Incident Heart Failure in General Practice: The Atherosclerosis Risk in Communities (ARIC) Study , 2012, Circulation. Heart failure.
[20] P. Harst,et al. The fibrosis marker galectin‐3 and outcome in the general population , 2012, Journal of internal medicine.
[21] Olle Melander,et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. , 2010, Journal of the American College of Cardiology.
[22] D. Levy,et al. Multimarker Approach for the Prediction of Heart Failure Incidence in the Community , 2010, Circulation.
[23] K. Bailey,et al. The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. , 2010, Journal of the American College of Cardiology.
[24] K. Bailey,et al. Participation bias in a population-based echocardiography study. , 2004, Annals of epidemiology.
[25] Douglas W Mahoney,et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. , 2003, JAMA.
[26] Douglas W Mahoney,et al. Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.
[27] John O'Quigley,et al. An application of changepoint methods in studying the effect of age on survival in breast cancer , 1999 .
[28] L. Melton,et al. History of the Rochester Epidemiology Project. , 1996, Mayo Clinic proceedings.
[29] F. Harrell,et al. Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .
[30] C. Escobar Cervantes,et al. [A randomized trial of intensive versus standard blood pressure control]. , 2016, Semergen.
[31] Biykem Bozkurt,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.